Narumi Nakagiri
Stock Analyst at Daiwa Capital
(0.96)
# 2,053
Out of 4,479 analysts
6
Total ratings
66.67%
Success rate
-1.99%
Average return
Main Sectors:
Top Industries:
4 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Upgrades: Buy | $320 | $310.77 | +2.97% | 2 | Dec 21, 2023 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Neutral | $68 → $54 | $40.45 | +33.50% | 1 | Nov 2, 2023 | |
| PFE Pfizer | Downgrades: Neutral | $38 | $27.83 | +36.54% | 2 | May 11, 2023 | |
| MRK Merck & Co. | Upgrades: Outperform | $89 → $102 | $127.72 | -20.14% | 1 | Jul 7, 2022 |
Amgen
Dec 21, 2023
Upgrades: Buy
Price Target: $320
Current: $310.77
Upside: +2.97%
Bristol-Myers Squibb Company
Nov 2, 2023
Downgrades: Neutral
Price Target: $68 → $54
Current: $40.45
Upside: +33.50%
Pfizer
May 11, 2023
Downgrades: Neutral
Price Target: $38
Current: $27.83
Upside: +36.54%
Merck & Co.
Jul 7, 2022
Upgrades: Outperform
Price Target: $89 → $102
Current: $127.72
Upside: -20.14%